Viral Hepatitis C Therapy: Pharmacokinetic and Pharmacodynamic Considerations (original) (raw)

• Lavanchy D. Evolving epidemiology of hepatitis C virus. Clin Microbiol Infect. 2011;17(2):107–15.
  PubMed CAS Google Scholar
• Afdhal NH. The natural history of hepatitis C. Semin Liver Dis. 2004;24(Suppl 2):3–8.
  PubMed Google Scholar
• Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL Jr, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002;347(13):975–82.
  PubMed CAS Google Scholar
• Khuroo MS, Khuroo MS, Dahab ST. Meta-analysis: a randomized trial of peginterferon plus ribavirin for the initial treatment of chronic hepatitis C genotype 4. Aliment Pharmacol Ther. 2004;20(9):931–8.
  PubMed CAS Google Scholar
• Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet. 2001;358(9286):958–65.
  PubMed CAS Google Scholar
• Zeuzem S, Hultcrantz R, Bourliere M, Goeser T, Marcellin P, Sanchez-Tapias J, et al. Peginterferon alfa-2b plus ribavirin for treatment of chronic hepatitis C in previously untreated patients infected with HCV genotypes 2 or 3. J Hepatol. 2004;40(6):993–9.
  PubMed CAS Google Scholar
• Poordad F, McCone J Jr, Bacon BR, Bruno S, Manns MP, Sulkowski MS, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med. 2011;364(13):1195–206.
  PubMed Central PubMed CAS Google Scholar
• Jacobson IM, McHutchison JG, Dusheiko G, Di Bisceglie AM, Reddy KR, Bzowej NH, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med. 2011;364(25):2405–16.
  PubMed CAS Google Scholar
• FDA. Olysio prescribing information. 2013. http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/205123s001lbl.pdf. Accessed 19 March 2014.
• FDA. Sovaldi prescribing information. 2013. http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/204671s000lbl.pdf. Accessed 19 March 2014.
• EMA. Sovaldi; product information. 2014. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002798/WC500160597.pdf. Accessed 19 March 2014.
• European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol. 2011;55(2):245–64.
  Google Scholar
• Ghany MG, Strader DB, Thomas DL, Seeff LB; American Association for the Study of Liver Diseases. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology (Baltimore, Md). 2009;49(4):1335–74.
• Ghany MG, Nelson DR, Strader DB, Thomas DL, Seeff LB; American Association for Study of Liver Diseases. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology (Baltimore, Md). 2011;54(4):1433–44.
• European Association for the Study of the Liver. EASL clinical practice guidelines: management of hepatitis C virus infection. J Hepatol. 2014;60(1):392–420.
  Google Scholar
• Lamers MH, Broekman MM, Boucher CA, Brouwer JT, Burger DM, van Hoek B, et al. Treatment of hepatitis C monoinfection in adults—Dutch national guidelines. Neth J Med. 2013;71(7):377–85.
  PubMed CAS Google Scholar
• Sen GC. Viruses and interferons. Annu Rev Microbiol. 2001;55:255–81.
  PubMed CAS Google Scholar
• Feld JJ, Hoofnagle JH. Mechanism of action of interferon and ribavirin in treatment of hepatitis C. Nature. 2005;436(7053):967–72.
  PubMed CAS Google Scholar
• Sidwell RW, Huffman JH, Khare GP, Allen LB, Witkowski JT, Robins RK. Broad-spectrum antiviral activity of Virazole: 1-beta-d-ribofuranosyl-1,2,4-triazole-3-carboxamide. Science (New York, NY). 1972;25;177(4050):705–6.
• Paeshuyse J, Dallmeier K, Neyts J. Ribavirin for the treatment of chronic hepatitis C virus infection: a review of the proposed mechanisms of action. Curr Opin Virol. 2011;1(6):590–8.
  PubMed CAS Google Scholar
• Kim CW, Chang KM. Hepatitis C virus: virology and life cycle. Clin Mol Hepatol. 2013;19(1):17–25.
  PubMed Central PubMed CAS Google Scholar
• Venkatraman S. Discovery of boceprevir, a direct-acting NS3/4A protease inhibitor for treatment of chronic hepatitis C infections. Trends Pharmacol Sci. 2012;33(5):289–94.
  PubMed CAS Google Scholar
• Perni RB, Almquist SJ, Byrn RA, Chandorkar G, Chaturvedi PR, Courtney LF, et al. Preclinical profile of VX-950, a potent, selective, and orally bioavailable inhibitor of hepatitis C virus NS3-4A serine protease. Antimicrob Agents Chemother. 2006;50(3):899–909.
  PubMed Central PubMed CAS Google Scholar
• Lin TI, Lenz O, Fanning G, Verbinnen T, Delouvroy F, Scholliers A, et al. In vitro activity and preclinical profile of TMC435350, a potent hepatitis C virus protease inhibitor. Antimicrob Agents Chemother. 2009;53(4):1377–85.
  PubMed Central PubMed CAS Google Scholar
• Bartenschlager R, Lohmann V, Penin F. The molecular and structural basis of advanced antiviral therapy for hepatitis C virus infection. Nat Rev Microbiol. 2013;11(7):482–96.
  PubMed CAS Google Scholar
• Sofia MJ, Bao D, Chang W, Du J, Nagarathnam D, Rachakonda S, et al. Discovery of a beta-d-2’-deoxy-2’-alpha-fluoro-2’-beta-C-methyluridine nucleotide prodrug (PSI-7977) for the treatment of hepatitis C virus. J Med Chem. 2010;53(19):7202–18.
  PubMed CAS Google Scholar
• FDA. Roferon-A prescribing information. 2006. http://www.accessdata.fda.gov/drugsatfda_docs/label/2006/103145s5060LBL.pdf. Accessed 9 July 2013.
• FDA. Intron A prescribing information. 2011. http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/103132s5161lbl.pdf. Accessed 9 July 2013.
• Reddy KR. Development and pharmacokinetics and pharmacodynamics of pegylated interferon alfa-2a (40 kD). Semin Liver Dis. 2004;24(Suppl 2):33–8.
  PubMed CAS Google Scholar
• Pedder SC. Pegylation of interferon alfa: structural and pharmacokinetic properties. Semin Liver Dis. 2003;23(Suppl 1):19–22.
  PubMed Google Scholar
• Thomas T, Foster G. Nanomedicines in the treatment of chronic hepatitis C—focus on pegylated interferon alpha-2a. Int J Nanomed. 2007;2(1):19–24.
  CAS Google Scholar
• Foster GR. Review article: pegylated interferons: chemical and clinical differences. Aliment Pharmacol Ther. 2004;20(8):825–30.
  PubMed CAS Google Scholar
• EMA. PegIntron product information. 2014. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000280/WC500039388.pdf. Accessed 19 March 2014.
• EMA. Pegasys product information. 2013. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000395/WC500039195.pdf. Accessed 19 March 2014.
• FDA. Pegasys prescribing information. 2013. http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/103964s5245lbl.pdf. Accessed 19 March 2014.
• FDA. PegIntron prescribing information. 2013. http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/103949s5259lbl.pdf. Accessed 19 March 2014.
• Caliceti P. Pharmacokinetics of pegylated interferons: what is misleading? Dig liver Dis. 2004;36(Suppl 3):S334–9.
  PubMed CAS Google Scholar
• Brennan BJ, Morcos PN, Wang K, Blotner SD, Morrison R, Hagedorn CH, et al. The pharmacokinetics of peginterferon alfa-2a and ribavirin in African American, Hispanic and Caucasian patients with chronic hepatitis C. Aliment Pharmacol Ther. 2012;35(10):1209–20.
  PubMed CAS Google Scholar
• Brennan BJ, Xu ZX, Grippo JF. Evaluation of the absolute bioavailability of pegylated interferon alfa-2a after subcutaneous administration to healthy male volunteers: an open-label, randomized, parallel-group study. Clin Ther. 2012;34(9):1883–91.
  PubMed CAS Google Scholar
• Bruno R, Sacchi P, Ciappina V, Zochetti C, Patruno S, Maiocchi L, et al. Viral dynamics and pharmacokinetics of peginterferon alpha-2a and peginterferon alpha-2b in naive patients with chronic hepatitis c: a randomized, controlled study. Antivir Ther. 2004;9(4):491–7.
  PubMed CAS Google Scholar
• Keam SJ, Cvetkovic RS. Peginterferon-alpha-2a (40 kD) plus ribavirin: a review of its use in the management of chronic hepatitis C mono-infection. Drugs. 2008;68(9):1273–317.
  PubMed CAS Google Scholar
• Perry CM, Jarvis B. Peginterferon-alpha-2a (40 kD): a review of its use in the management of chronic hepatitis C. Drugs. 2001;61(15):2263–88.
  PubMed CAS Google Scholar
• Varunok P, Lawitz E, Beavers KL, Matusow G, Leong R, Lambert N, et al. Evaluation of pharmacokinetics, user handling, and tolerability of peginterferon alfa-2a (40 kDa) delivered via a disposable autoinjector device. Patient Prefer Adher. 2011;5:587–99.
  Google Scholar
• Keating GM, Curran MP. Peginterferon-alpha-2a (40kD) plus ribavirin: a review of its use in the management of chronic hepatitis C. Drugs. 2003;63(7):701–30.
  PubMed CAS Google Scholar
• Glue P, Fang JW, Rouzier-Panis R, Raffanel C, Sabo R, Gupta SK, et al. Pegylated interferon-alpha2b: pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data. Hepatitis C Intervention Therapy Group. Clin Pharmacol Ther. 2000;68(5):556–67.
  PubMed CAS Google Scholar
• Glue P. The clinical pharmacology of ribavirin. Semin Liver Dis. 1999;19(Suppl 1):17–24.
  PubMed CAS Google Scholar
• FDA. Copegus prescribing information. http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021511s026lbl.pdf. Accessed 19 March 2014.
• EMA. Rebetol product information. 2013. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000246/WC500048210.pdf. Accessed 19 March 2014.
• FDA. Rebetol prescribing information. 2013. http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/020903s052,021546s008lbl.pdf. Accessed 19 March 2014.
• Moss AM, Endres CJ, Ruiz-Garcia A, Choi DS, Unadkat JD. Role of the equilibrative and concentrative nucleoside transporters in the intestinal absorption of the nucleoside drug, ribavirin, in wild-type and Ent1(−/−) mice. Mol Pharm. 2012;9(9):2442–9.
  PubMed Central PubMed CAS Google Scholar
• Endres CJ, Moss AM, Govindarajan R, Choi DS, Unadkat JD. The role of nucleoside transporters in the erythrocyte disposition and oral absorption of ribavirin in the wild-type and equilibrative nucleoside transporter 1−/− mice. J Pharmacol Exp Ther. 2009;331(1):287–96.
  PubMed Central PubMed CAS Google Scholar
• Li L, Koo SH, Limenta LM, Han L, Hashim KB, Quek HH, et al. Effect of dietary purines on the pharmacokinetics of orally administered ribavirin. J Clin Pharmacol. 2009;49(6):661–7.
  PubMed CAS Google Scholar
• Jarvis SM, Thorn JA, Glue P. Ribavirin uptake by human erythrocytes and the involvement of nitrobenzylthioinosine-sensitive (es)-nucleoside transporters. Br J Pharmacol. 1998;123(8):1587–92.
  PubMed Central PubMed CAS Google Scholar
• Fukuchi Y, Furihata T, Hashizume M, Iikura M, Chiba K. Characterization of ribavirin uptake systems in human hepatocytes. J Hepatol. 2010;52(4):486–92.
  PubMed CAS Google Scholar
• Lertora JJ, Rege AB, Lacour JT, Ferencz N, George WJ, VanDyke RB, et al. Pharmacokinetics and long-term tolerance to ribavirin in asymptomatic patients infected with human immunodeficiency virus. Clin Pharmacol Ther. 1991;50(4):442–9.
  PubMed CAS Google Scholar
• Tsubota A, Shimada N, Yoshizawa K, Furihata T, Agata R, Yumoto Y, et al. Contribution of ribavirin transporter gene polymorphism to treatment response in peginterferon plus ribavirin therapy for HCV genotype 1b patients. Liver Int. 2012;32(5):826–36.
  PubMed CAS Google Scholar
• Jen JF, Glue P, Gupta S, Zambas D, Hajian G. Population pharmacokinetic and pharmacodynamic analysis of ribavirin in patients with chronic hepatitis C. Ther Drug Monit. 2000;22(5):555–65.
  PubMed CAS Google Scholar
• Merck. Boceprevir clinical pharmacology and biopharmaceutics review(s). 2011. http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/202258orig1s000clinpharmr.pdf. Accessed 11 March 2014.
• EMA. Victrelis product information. 2013. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002332/WC500109786.pdf. Accessed 19 March 2014.
• FDA. Victrelis prescribing information. 2013. http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/202258s009lbl.pdf. Accessed 19 March 2014.
• Ghosal A, Yuan Y, Tong W, Su AD, Gu C, Chowdhury SK, et al. Characterization of human liver enzymes involved in the biotransformation of boceprevir, a hepatitis C virus protease inhibitor. Drug Metab Dispos Biol Fate Chem. 2011;39(3):510–21.
  PubMed CAS Google Scholar
• Chu X, Cai X, Cui D, Tang C, Ghosal A, Chan G, et al. In vitro assessment of drug–drug interaction potential of boceprevir associated with drug metabolizing enzymes and transporters. Drug Metab Dispos Biol Fate Chem. 2013;41(3):668–81.
  PubMed CAS Google Scholar
• EMA. Incivo product information. 2013. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002313/WC500115529.pdf. Accessed 19 March 2014.
• FDA. Incivek prescribing information. 2013. http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/201917s012lbl.pdf. Accessed 19 March 2014.
• Vertex Pharmaceuticals. Telaprevir clinical pharmacology and biopharmaceutics review(s). 2010. http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/201917Orig1s000ClinPharmR.pdf. Accessed 9 March 2014.
• Garg V, Kauffman RS, Beaumont M, van Heeswijk RP. Telaprevir: pharmacokinetics and drug interactions. Antivir Ther. 2012;17(7):1211–21.
  PubMed CAS Google Scholar
• Reesink HW, Fanning GC, Farha KA, Weegink C, Van Vliet A, Van ‘t Klooster G, et al. Rapid HCV-RNA decline with once daily TMC435: a phase I study in healthy volunteers and hepatitis C patients. Gastroenterology. 2010;138(3):913–21.
• Dickinson L, Khoo S, Back D. Differences in the pharmacokinetics of protease inhibitors between healthy volunteers and HIV-infected persons. Curr Opin HIV AIDS. 2008;3(3):296–305.
  PubMed Google Scholar
• Janssen. Simeprevir clinical pharmacology and biopharmaceutics review(s). 2013. http://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/205123Orig1s000ClinPharmR.pdf. Accessed 13 March 2014.
• Rodriguez-Torres M, Lawitz E, Kowdley KV, Nelson DR, Dejesus E, McHutchison JG, et al. Sofosbuvir (GS-7977) plus peginterferon/ribavirin in treatment-naive patients with HCV genotype 1: a randomized, 28-day, dose-ranging trial. J Hepatol. 2013;58(4):663–8.
  PubMed CAS Google Scholar
• Bailon P, Palleroni A, Schaffer CA, Spence CL, Fung WJ, Porter JE, et al. Rational design of a potent, long-lasting form of interferon: a 40 kDa branched polyethylene glycol-conjugated interferon alpha-2a for the treatment of hepatitis C. Bioconjug Chem. 2001;12(2):195–202.
  Google Scholar
• Youngster S, Wang YS, Grace M, Bausch J, Bordens R, Wyss DF. Structure, biology, and therapeutic implications of pegylated interferon alpha-2b. Curr Pharm Des. 2002;8(24):2139–57.
  PubMed CAS Google Scholar
• Reddy KR, Wright TL, Pockros PJ, Shiffman M, Everson G, Reindollar R, et al. Efficacy and safety of pegylated (40-kd) interferon alpha-2a compared with interferon alpha-2a in noncirrhotic patients with chronic hepatitis C. Hepatology (Baltimore, Md). 2001;33(2):433–8.
• Zeuzem S, Feinman SV, Rasenack J, Heathcote EJ, Lai MY, Gane E, et al. Peginterferon alfa-2a in patients with chronic hepatitis C. N Engl J Med. 2000;343(23):1666–72.
  PubMed CAS Google Scholar
• Heathcote EJ, Shiffman ML, Cooksley WG, Dusheiko GM, Lee SS, Balart L, et al. Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis. N Engl J Med. 2000;343(23):1673–80.
  PubMed CAS Google Scholar
• Lindsay KL, Trepo C, Heintges T, Shiffman ML, Gordon SC, Hoefs JC, et al. A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C. Hepatology (Baltimore, Md). 2001;34(2):395–3.
• Bruno R, Sacchi P, Scagnolari C, Torriani F, Maiocchi L, Patruno S, et al. Pharmacodynamics of peginterferon alpha-2a and peginterferon alpha-2b in interferon-naive patients with chronic hepatitis C: a randomized, controlled study. Aliment Pharmacol Ther. 2007;26(3):369–76.
  PubMed CAS Google Scholar
• Shindo M, Hamada K, Morikawa T, Harano Y, Nakajima T, Okuno T. In vivo interferon system assessed by 2’-5’ oligoadenylate synthetase activity in chronic hepatitis C virus patients treated with pegylated interferon and ribavirin. Hepatol Res. 2008;38(12):1213–20.
  PubMed CAS Google Scholar
• Francois C, Descamps V, Brochot E, Bernard I, Canva V, Mathurin P, et al. Relationship between the hepatitis C viral load and the serum interferon concentration during the first week of peginterferon-alpha-2b-ribavirin combination therapy. J Med Virol. 2010;82(10):1640–6.
  PubMed CAS Google Scholar
• Formann E, Jessner W, Bennett L, Ferenci P. Twice-weekly administration of peginterferon-alpha-2b improves viral kinetics in patients with chronic hepatitis C genotype 1. J Viral Hepat. 2003;10(4):271–6.
  PubMed CAS Google Scholar
• Di Bisceglie AM, Ghalib RH, Hamzeh FM, Rustgi VK. Early virologic response after peginterferon alpha-2a plus ribavirin or peginterferon alpha-2b plus ribavirin treatment in patients with chronic hepatitis C. J Viral Hepat. 2007;14(10):721–9.
  PubMed Google Scholar
• Brochot E, Nguyen-Khac E, Duverlie G. Equal efficacy between the two types of peginterferon on HCV: a matter of relapse? Antivir Res. 2013;98(1):1–3.
  PubMed CAS Google Scholar
• McHutchison JG, Lawitz EJ, Shiffman ML, Muir AJ, Galler GW, McCone J, et al. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med. 2009;361(6):580–93.
  PubMed CAS Google Scholar
• Flori N, Funakoshi N, Duny Y, Valats JC, Bismuth M, Christophorou D, et al. Pegylated interferon-alpha2a and ribavirin versus pegylated interferon-alpha2b and ribavirin in chronic hepatitis C: a meta-analysis. Drugs. 2013;73(3):263–77.
  PubMed CAS Google Scholar
• Romero-Gomez M, Planas R, Ampuero J, Sola R, Garcia-Samaniego J, Diago M, et al. Meta-analysis: pegylated interferon alpha-2a achieves higher early virological responses than alpha-2b in chronic hepatitis C. Aliment Pharmacol Ther. 2013;37(11):1065–73.
  PubMed CAS Google Scholar
• Marcellin P, Forns X, Goeser T, Ferenci P, Nevens F, Carosi G, et al. Telaprevir is effective given every 8 or 12 hours with ribavirin and peginterferon alfa-2a or -2b to patients with chronic hepatitis C. Gastroenterology. 2011;140(2):459–68.
  PubMed CAS Google Scholar
• Jacobson IM, Brown RS Jr, Freilich B, Afdhal N, Kwo PY, Santoro J, et al. Peginterferon alfa-2b and weight-based or flat-dose ribavirin in chronic hepatitis C patients: a randomized trial. Hepatology (Baltimore, Md). 2007;46(4):971–81.
• Jacobson IM, Brown RS Jr, McCone J, Black M, Albert C, Dragutsky, et al. Impact of weight-based ribavirin with peginterferon alfa-2b in African Americans with hepatitis C virus genotype 1. Hepatology (Baltimore, Md). 2007;46(4):982–90.
  CAS Google Scholar
• Snoeck E, Wade JR, Duff F, Lamb M, Jorga K. Predicting sustained virological response and anaemia in chronic hepatitis C patients treated with peginterferon alfa-2a (40KD) plus ribavirin. Br J Clin Pharmacol. 2006;62(6):699–709.
  PubMed Central PubMed CAS Google Scholar
• Hadziyannis SJ, Sette H Jr, Morgan TR, Balan V, Diago M, Marcellin P, et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med. 2004;140(5):346–55.
  PubMed CAS Google Scholar
• Larrat S, Stanke-Labesque F, Plages A, Zarski JP, Bessard G, Souvignet C. Ribavirin quantification in combination treatment of chronic hepatitis C. Antimicrob Agents Chemother. 2003;47(1):124–9.
  PubMed Central PubMed CAS Google Scholar
• Morello J, Rodriguez-Novoa S, Jimenez-Nacher I, Soriano V. Usefulness of monitoring ribavirin plasma concentrations to improve treatment response in patients with chronic hepatitis C. J Antimicrob Chemother. 2008;62(6):1174–80.
  PubMed CAS Google Scholar
• Chan AH, Partovi N, Ensom MH. The utility of therapeutic drug monitoring for ribavirin in patients with chronic hepatitis C—a critical review. Ann Pharmacother. 2009;43(12):2044–63.
  PubMed CAS Google Scholar
• Brochot E, Castelain S, Duverlie G, Capron D, Nguyen-Khac E, Francois C. Ribavirin monitoring in chronic hepatitis C therapy: anaemia versus efficacy. Antivir Ther. 2010;15(5):687–95.
  PubMed CAS Google Scholar
• Loustaud-Ratti V, Carrier P, Rousseau A, Maynard M, Babany G, Alain S, et al. Pharmacological exposure to ribavirin: a key player in the complex network of factors implicated in virological response and anaemia in hepatitis C treatment. Dig Liver Dis. 2011;43(11):850–5.
  PubMed CAS Google Scholar
• Loustaud-Ratti V, Alain S, Rousseau A, Hubert IF, Sauvage FL, Marquet P, et al. Ribavirin exposure after the first dose is predictive of sustained virological response in chronic hepatitis C. Hepatology (Baltimore, Md). 2008;47(5):1453–61.
• Arase Y, Ikeda K, Tsubota A, Suzuki F, Suzuki Y, Saitoh S, et al. Significance of serum ribavirin concentration in combination therapy of interferon and ribavirin for chronic hepatitis C. Intervirology. 2005;48(2–3):138–44.
  PubMed CAS Google Scholar
• Dominguez S, Ghosn J, Cassard B, Melica G, Poizot-Martin I, Solas C, et al. Erythrocyte and plasma ribavirin concentrations in the assessment of early and sustained virological responses to pegylated interferon-alpha 2a and ribavirin in patients coinfected with hepatitis C virus and HIV. J Antimicrob Chemother. 2012;67(6):1449–52.
  PubMed CAS Google Scholar
• Baiocchi L, De Leonardis F, Delle Monache M, Nosotti L, Conti RL, Lenci I, et al. Plasma/erythrocyte ribavirin ×100 ratio as an indicator of sustained virological response in HCV genotype 1 patients with early virological response. Antivir Ther. 2010;15(4):633–9.
  Google Scholar
• De Franceschi L, Fattovich G, Turrini F, Ayi K, Brugnara C, Manzato F, et al. Hemolytic anemia induced by ribavirin therapy in patients with chronic hepatitis C virus infection: role of membrane oxidative damage. Hepatology (Baltimore, Md). 200031(4):997–4.
• Poynard T, Marcellin P, Lee SS, Niederau C, Minuk GS, Ideo G, et al. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet. 1998;352(9138):1426–32.
  PubMed CAS Google Scholar
• Lindahl K, Schvarcz R, Bruchfeld A, Stahle L. Evidence that plasma concentration rather than dose per kilogram body weight predicts ribavirin-induced anaemia. J Viral Hepat. 2004;11(1):84–7.
  PubMed CAS Google Scholar
• Smee DF, Matthews TR. Metabolism of ribavirin in respiratory syncytial virus-infected and uninfected cells. Antimicrob Agents Chemother. 1986;30(1):117–21.
  PubMed Central PubMed CAS Google Scholar
• Fellay J, Thompson AJ, Ge D, Gumbs CE, Urban TJ, Shianna KV, et al. ITPA gene variants protect against anaemia in patients treated for chronic hepatitis C. Nature. 2010;464(7287):405–8.
  PubMed CAS Google Scholar
• Hofer H, Donnerer J, Sator K, Staufer K, Scherzer TM, Dejaco C, et al. Seminal fluid ribavirin level and functional semen parameters in patients with chronic hepatitis C on antiviral combination therapy. J Hepatol. 2010;52(6):812–6.
  PubMed CAS Google Scholar
• Lindahl K, Stahle L, Bruchfeld A, Schvarcz R. High-dose ribavirin in combination with standard dose peginterferon for treatment of patients with chronic hepatitis C. Hepatology (Baltimore, Md). 2005;41(2):275–9.
• Trepo C. RIBAJUSTE clinical trial investigating the efficacy and safety of dose adaptation of ribavirin. 2013. http://clinicaltrials.gov/ct2/show/NCT00485342?term=ribajuste&rank=1. Accessed 20 Dec 2013.
• EMA. Victrelis: EPAR public assessment report. 2011. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002332/WC500109789.pdf. Accessed 10 December 2013.
• Reesink HW, Zeuzem S, Weegink CJ, Forestier N, van Vliet A, van de Wetering de Rooij J, et al. Rapid decline of viral RNA in hepatitis C patients treated with VX-950: a phase Ib, placebo-controlled, randomized study. Gastroenterology. 2006131(4):997–2.
• EMA. Incivo: EPAR public assessment report. 2011. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002313/WC500115532.pdf. Accessed 10 Dec 2013.
• Furusyo N, Ogawa E, Murata M, Toyoda K, Ohnishi H, Eiraku K, et al. Therapeutic drug monitoring of telaprevir in chronic hepatitis C patients receiving telaprevir-based triple therapy is useful for predicting virological response. J Antimicrob Chemother. 2014;69(2):483–90.
  PubMed CAS Google Scholar
• Sciences G. Sofosbuvir clinical pharmacology and biopharmaceutics review(s). 2013. http://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/204671Orig1s000ClinPharmR.pdf. Accessed 15 Mar 2014.
• Kunze A, Huwyler J, Camenisch G, Gutmann H. Interaction of the antiviral drug telaprevir with renal and hepatic drug transporters. Biochem Pharmacol. 2012;84(8):1096–102.
  PubMed CAS Google Scholar
• Fujita Y, Noguchi K, Suzuki T, Katayama K, Sugimoto Y. Biochemical interaction of anti-HCV telaprevir with the ABC transporters P-glycoprotein and breast cancer resistance protein. BMC Res Notes. 2013;6:445.
  PubMed Google Scholar
• Kiser JJ, Burton JR, Anderson PL, Everson GT. Review and management of drug interactions with boceprevir and telaprevir. Hepatology (Baltimore, Md). 2012;55(5):1620–8.
• Burger D, Back D, Buggisch P, Buti M, Craxi A, Foster G, et al. Clinical management of drug–drug interactions in HCV therapy: Challenges and solutions. J Hepatol. 2013;58(4):792–800.
  PubMed CAS Google Scholar
• Back D, Else L. The importance of drug–drug interactions in the DAA era. Dig Liver Dis. 2013;30(45 Suppl 5):S343–8.
  Google Scholar
• Maasoumy B, Port K, Calle Serrano B, Markova AA, Sollik L, Manns MP, et al. The clinical significance of drug–drug interactions in the era of direct-acting anti-viral agents against chronic hepatitis C. Aliment Pharmacol Ther. 2013;38(11–12):1365–72.
  Google Scholar
• Verbeeck RK. Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction. Eur J Clin Pharmacol. 2008;64(12):1147–61.
  PubMed CAS Google Scholar
• Glue P, Schenker S, Gupta S, Clement RP, Zambas D, Salfi M. The single dose pharmacokinetics of ribavirin in subjects with chronic liver disease. Br J Clin Pharmacol. 2000;49(5):417–21.
  PubMed Central PubMed CAS Google Scholar
• Treitel M, Marbury T, Preston RA, Triantafyllou I, Feely W, O’Mara E, et al. Single-dose pharmacokinetics of boceprevir in subjects with impaired hepatic or renal function. Clin Pharmacokinet. 2012;51(9):619–28.
  PubMed CAS Google Scholar
• Hezode C, Fontaine H, Dorival C, Larrey D, Zoulim F, Canva V, et al. Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC) - NCT01514890. J Hepatol. 2013;59(3):434–41.
  PubMed Google Scholar
• Gupta SK, Swan SK, Marbury T, Smith W, Schwartz S, Kolz K, et al. Multiple-dose pharmacokinetics of peginterferon alfa-2b in patients with renal insufficiency. Br J Clin Pharmacol. 2007;64(6):726–32.
  PubMed Central PubMed CAS Google Scholar
• Barril G, Quiroga JA, Sanz P, Rodriguez-Salvanes F, Selgas R, Carreno V. Pegylated interferon-alpha2a kinetics during experimental haemodialysis: impact of permeability and pore size of dialysers. Aliment Pharmacol Ther. 2004;20(1):37–44.
  PubMed CAS Google Scholar
• Gupta SK, Kantesaria B, Glue P. Pharmacokinetics, safety, and tolerability of ribavirin in hemodialysis-dependent patients. Eur J Clin Pharmacol. 2012;68(4):415–8.
  PubMed CAS Google Scholar
• Bruchfeld A, Lindahl K, Reichard O, Carlsson T, Schvarcz R. Pegylated interferon and ribavirin treatment for hepatitis C in haemodialysis patients. J Viral Hepat. 2006;13(5):316–21.
  PubMed CAS Google Scholar
• Tseng PL, Chen TC, Chien YS, Hung CH, Yen YH, Chang KC, et al. Efficacy and safety of pegylated interferon alfa-2b and ribavirin combination therapy versus pegylated interferon monotherapy in hemodialysis patients: a comparison of 2 sequentially treated cohorts. Am J Kidney Dis. 2013;62(4):789–95.
  PubMed CAS Google Scholar
• Dumortier J, Guillaud O, Gagnieu MC, Janbon B, Juillard L, Morelon E, et al. Anti-viral triple therapy with telaprevir in haemodialysed HCV patients: is it feasible? J Clin Virol. 2013;56(2):146–9.
  PubMed CAS Google Scholar
• Egger M, May M, Chene G, Phillips AN, Ledergerber B, Dabis F, et al. Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet. 2002;360(9327):119–29.
  PubMed Google Scholar
• Lacombe K, Rockstroh J. HIV and viral hepatitis coinfections: advances and challenges. Gut. 2012;61(Suppl 1):i47–58.
  PubMed CAS Google Scholar
• Sherman KE, Rouster SD, Chung RT, Rajicic N. Hepatitis C Virus prevalence among patients infected with Human Immunodeficiency Virus: a cross-sectional analysis of the US adult AIDS Clinical Trials Group. Clin Infect Dis. 2002;34(6):831–7.
  PubMed Google Scholar
• Weber R, Ruppik M, Rickenbach M, Spoerri A, Furrer H, Battegay M, et al. Decreasing mortality and changing patterns of causes of death in the Swiss HIV Cohort Study. HIV Med. 2013;14(4):195–207.
  PubMed CAS Google Scholar
• Torriani FJ, Rodriguez-Torres M, Rockstroh JK, Lissen E, Gonzalez-Garcia J, Lazzarin A, et al. Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med. 2004;351(5):438–50.
  PubMed CAS Google Scholar
• Rodriguez-Torres M, Slim J, Bhatti L, Sterling R, Sulkowski M, Hassanein T, et al. Peginterferon alfa-2a plus ribavirin for HIV-HCV genotype 1 coinfected patients: a randomized international trial. HIV Clin Trials. 2012;13(3):142–52.
  PubMed CAS Google Scholar
• Sulkowski M, Pol S, Mallolas J, Fainboim H, Cooper C, Slim J, et al. Boceprevir versus placebo with pegylated interferon alfa-2b and ribavirin for treatment of hepatitis C virus genotype 1 in patients with HIV: a randomised, double-blind, controlled phase 2 trial. Lancet Infect Dis. 2013;13(7):597–605.
  PubMed CAS Google Scholar
• Sulkowski MS, Sherman KE, Dieterich DT, Bsharat M, Mahnke L, Rockstroh JK, et al. Combination therapy with telaprevir for chronic hepatitis C virus genotype 1 infection in patients with HIV: a randomized trial. Ann Intern Med. 2013;159(20):86–96
  Google Scholar
• Chastain CA, Naggie S. Treatment of genotype 1 HCV infection in the HIV coinfected patient in 2014. Curr HIV/AIDS Rep. 2013;10(4):408–19.
  PubMed Google Scholar
• Luetkemeyer AF, Havlir DV, Currier JS. CROI 2013: complications of HIV disease, viral hepatitis, and antiretroviral therapy. Top Antivir Med. 2013;21(2):62–74.
  PubMed Google Scholar
• Karageorgopoulos DE, El-Sherif O, Bhagani S, Khoo SH. Drug interactions between antiretrovirals and new or emerging direct-acting antivirals in HIV/hepatitis C virus coinfection. Curr Opin Infect Dis. 2014;27(1):36–45.
  PubMed CAS Google Scholar
• Gonzalez-Peralta RP, Kelly DA, Haber B, Molleston J, Murray KF, Jonas MM, et al. Interferon alfa-2b in combination with ribavirin for the treatment of chronic hepatitis C in children: efficacy, safety, and pharmacokinetics. Hepatology (Baltimore, Md). 2005;42(5):1010–8.
• Schwarz KB, Mohan P, Narkewicz MR, Molleston JP, Nash SR, Hu S, et al. Safety, efficacy and pharmacokinetics of peginterferon alpha2a (40 kd) in children with chronic hepatitis C. J Pediatr Gastroenterol Nutr. 2006;43(4):499–505.
  PubMed CAS Google Scholar
• Xu C, Gupta S, Krishna G, Cutler D, Wirth S, Galoppo C, et al. Population pharmacokinetics of peginterferon alfa-2b in pediatric patients with chronic hepatitis C. Eur J Clin Pharmacol. 2013;69(12):2045–54.
  PubMed CAS Google Scholar
• Schwarz KB, Gonzalez-Peralta RP, Murray KF, Molleston JP, Haber BA, Jonas MM, et al. The combination of ribavirin and peginterferon is superior to peginterferon and placebo for children and adolescents with chronic hepatitis C. Gastroenterology. 2011;140(2):450–8 e1.
  Google Scholar
• Wirth S, Ribes-Koninckx C, Calzado MA, Bortolotti F, Zancan L, Jara P, et al. High sustained virologic response rates in children with chronic hepatitis C receiving peginterferon alfa-2b plus ribavirin. J Hepatol. 2010;52(4):501–7.
  PubMed CAS Google Scholar
• Liang TJ, Ghany MG. Current and future therapies for hepatitis C virus infection. N Engl J Med. 2013;368(20):1907–17.
  PubMed Central PubMed CAS Google Scholar